Undisclosed T Cell Program
Cancer (Oncology)
PreclinicalActive
Key Facts
About Intune
Intune is a private, preclinical-stage biotech focused on developing T cell immunotherapies for oncology. The company aims to engineer next-generation T cell products to address significant unmet needs in cancer treatment. As a young company, it is in the early stages of research and development, building its platform and pipeline.
View full company profileTherapeutic Areas
Other Cancer (Oncology) Drugs
| Drug | Company | Phase |
|---|---|---|
| HemaMax | Neumedicines | Phase 2 |
| Undisclosed Cell Therapy Program | Modulus Therapeutics | Preclinical |
| In Vivo CAR-T Programs | GenVivo | Pre-clinical |